BioSpace News Archive

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.

Humanetics Corporation, a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry expert Jake R. Nunn to the Company’s Board of Directors.